Vetigenics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $6M

  • Investors
  • 6

Vetigenics General Information

Description

Operator of an animal health biotechnology company intended to improve the lives of companion animals through science and medicine. The company offers a proprietary, species-specific, phage display technology that creates safe, effective therapeutics to treat cancer, autoimmune, inflammatory, and infectious diseases, enabling veterinarians to improve the treatment options to offer pet parents for their beloved family members.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • B. Labs Cira Centre, 2929 Arch Street
  • Fourth Floor, Lab 436
  • Philadelphia, PA 19104
  • United States
Primary Industry
Other Commercial Services
Corporate Office
  • B. Labs Cira Centre, 2929 Arch Street
  • Fourth Floor, Lab 436
  • Philadelphia, PA 19104
  • United States

Vetigenics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vetigenics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Seed Round 03-Feb-2025 $6M Completed Clinical Trials - Phase 1
5. Angel (individual) 01-Sep-2023 Completed Clinical Trials - Phase 1
4. Angel (individual) 01-Aug-2022 Completed Pre-Clinical Trials
3. Grant 01-Oct-2021 Completed Pre-Clinical Trials
2. Grant 01-Jan-2018 $355K Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Vetigenics’s complete valuation and funding history, request access »

Vetigenics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Vetigenics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Vetigenics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an animal health biotechnology company intended to improve the lives of companion animals through science an
Other Commercial Services
Philadelphia, PA
10 As of 2025

San Diego, CA
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vetigenics Competitors (3)

One of Vetigenics’s 3 competitors is Vetmab Bio, a Venture Capital-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vetmab Bio Venture Capital-Backed San Diego, CA
PetMedix Formerly VC-backed Cambridge, United Kingdom
MabGenesis Venture Capital-Backed Yokohama, Japan
You’re viewing 3 of 3 competitors. Get the full list »

Vetigenics Patents

Vetigenics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3216131-A1 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) Pending 21-Apr-2021
EP-4326324-A1 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) Pending 21-Apr-2021
US-12110331-B2 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) Active 21-Apr-2021
US-20240109967-A1 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) Active 21-Apr-2021
US-20250171541-A1 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) Pending 21-Apr-2021 C07K16/2818
To view Vetigenics’s complete patent history, request access »

Vetigenics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vetigenics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Veterinary Angel Network for Entrepreneurs Angel Group Minority
Wilson Sonsini Goodrich & Rosati VC-Backed Company Minority
National Cancer Institute Government
Astralabs Accelerator/Incubator Minority
Penn Center for Innovation Accelerator/Incubator Minority
You’re viewing 5 of 6 investors. Get the full list »

Vetigenics FAQs

  • When was Vetigenics founded?

    Vetigenics was founded in 2017.

  • Where is Vetigenics headquartered?

    Vetigenics is headquartered in Philadelphia, PA.

  • What is the size of Vetigenics?

    Vetigenics has 10 total employees.

  • What industry is Vetigenics in?

    Vetigenics’s primary industry is Other Commercial Services.

  • Is Vetigenics a private or public company?

    Vetigenics is a Private company.

  • What is the current valuation of Vetigenics?

    The current valuation of Vetigenics is .

  • What is Vetigenics’s current revenue?

    The current revenue for Vetigenics is .

  • How much funding has Vetigenics raised over time?

    Vetigenics has raised $7.25M.

  • Who are Vetigenics’s investors?

    Veterinary Angel Network for Entrepreneurs, Wilson Sonsini Goodrich & Rosati, National Cancer Institute, Astralabs, and Penn Center for Innovation are 5 of 6 investors who have invested in Vetigenics.

  • Who are Vetigenics’s competitors?

    Vetmab Bio, PetMedix, and MabGenesis are competitors of Vetigenics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process